Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression

摘要

The inventive method relates to a method for the determination of susceptibility or diagnosis of autism or autism spectrum disorders. Diagnosis or determination of susceptibility determinations are predicated on quantitative analysis of endocannibinoid levels or endocannibinoid receptor expression.

主权项

1. A method of diagnosing or determining susceptibility to developing, autism or autism spectrum disorder comprising administering acetaminophen to an individual and quantitating the levels of one or more endocannibinoids in plasma of said individual and comparing said level or levels with that of a normal individual, wherein said acetaminophen is administered at 10 mg/Kg to 100 mg/Kg, and wherein said endocannibinoid is selected from the group consisting of Δ9-tetrahydrocannabinol (THC); N-arachidonoylethanolamine (anandamide); N-palmitoylethanolamine (PEA); cannabidiol (CBD); 2-arachidonoyl glycerol (2-AG); and N-oleoylethanolamine (OEA), wherein diagnosis or a determination of susceptibility is made if the quantitated endocannibinoid level of said individual is different from the mean of the range of individuals, of the same age group, without autism or autism spectrum disorders and wherein a diagnosis or determination of susceptibility is made if the said N-arachidonoylethanolamine (anandamide) concentration plasma is changed at least forty five to seventy five percent (45% to 75%) or if the said 2-arachidonoyl glycerol (2-AG) level is changed at least twenty percent (20%) from the mean in non-autistic individuals or individuals without autism spectrum disorders of a similar age group.